Lake Street Capital Reaffirms Hold Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “hold” rating reaffirmed by Lake Street Capital in a research report issued on Monday,Benzinga reports. They currently have a $4.10 target price on the stock, down from their previous target price of $7.00. Lake Street Capital’s price objective would indicate a potential upside of 3.14% from the company’s previous close.

Several other equities analysts have also recently issued reports on CKPT. D. Boral Capital reiterated a “buy” rating and set a $4.80 price target (down previously from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a report on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT traded up $1.51 during trading hours on Monday, hitting $3.98. The company’s stock had a trading volume of 52,361,802 shares, compared to its average volume of 1,932,363. The business has a 50-day simple moving average of $3.10 and a 200-day simple moving average of $3.08. The stock has a market cap of $194.11 million, a price-to-earnings ratio of -2.17 and a beta of 1.41. Checkpoint Therapeutics has a 12 month low of $1.38 and a 12 month high of $4.50.

Insider Buying and Selling

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 9,233 shares of Checkpoint Therapeutics stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the completion of the transaction, the chief executive officer now directly owns 3,785,350 shares of the company’s stock, valued at approximately $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William Garrett Gray sold 268,432 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the sale, the chief financial officer now owns 1,032,754 shares in the company, valued at approximately $4,141,343.54. The trade was a 20.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 582,336 shares of company stock worth $2,156,801 in the last three months. 2.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in shares of Checkpoint Therapeutics in the third quarter worth $30,000. SBI Securities Co. Ltd. purchased a new stake in Checkpoint Therapeutics in the fourth quarter worth approximately $32,000. PUREfi Wealth LLC bought a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at about $32,000. Stifel Financial Corp bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. Finally, Ameriflex Group Inc. purchased a new stake in shares of Checkpoint Therapeutics in the 4th quarter worth $32,000. 22.00% of the stock is owned by institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.